Effect of brief nicotine corrective messaging on nicotine beliefs in persons who use opioids.

Plain-language guide to PMID 34291993 (2022): pilot randomized controlled trial of Therapeutic nicotine (patch, non-peptide).

Key Facts

PMID: 34291993
Journal: Experimental and clinical psychopharmacology
Year: 2022
Study type: Randomized Controlled Trial
Authors: Parker MA et al. (3 authors)
DOI: 10.1037/pha0000497

What This Study Did, in Plain Language

What Was Tested

The paper reports a study of Therapeutic nicotine (patch, non-peptide), published as a randomized controlled trial.

Participants ages 18 and older were recruited via Amazon Mechanical Turk to complete a 20-min online survey in April/May 2020 to assess relationships between opioid use, smoking, and other behaviors.

Why It Was Studied

This pilot study tested the effect of a brief nicotine education messaging exposure on beliefs about nicotine, nicotine-replacement therapy (NRT), and e-cigarettes.

Beliefs about nicotine, NRT, and e-cigarettes were asked of all participants; this occurred after message exposure for the nicotine education condition.

Who Took Part

The age groups tagged for this paper are teenagers and adults.

Participants with past-month extra-medical opioid use completed questions on background characteristics and literacy and then were randomized in a 2:1 ratio of two conditions: nicotine education (n = 362) or no message control (n = 181).

How the Study Was Run

The researchers set it up as a randomized and pilot study.

The participants were allocated by chance, so the Therapeutic nicotine (patch, non-peptide) group and the comparison group should start out alike.

It is described as a pilot, a small early test of whether a larger Therapeutic nicotine (patch, non-peptide) study would be practical.

What Was Measured

This pilot study tested the effect of a brief nicotine education messaging exposure on beliefs about nicotine, nicotine-replacement therapy (NRT), and e-cigarettes.

The subject headings attached to it are Nicotine, Analgesics, Opioid, Smoking Cessation, Electronic Nicotine Delivery Systems, Pilot Projects, Tobacco Use Cessation Devices and Opioid-Related Disorders.

What This Means in Plain Language

The paper is a randomized and pilot study of Therapeutic nicotine (patch, non-peptide).

The publication is from 2022 (Experimental and clinical psychopharmacology), a journal based in United States.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.

Our Notes on the Compound

Therapeutic nicotine (patch, non-peptide): Pure nicotine as a signaling tool, separated from smoking and vaping.

Therapeutic nicotine (patch, non-peptide) in the library

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.